BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
5 years
USD
Become a Premium user to unlock the Score details
Price
per share adjusted in USD$44.68
Price-0.98%
-$0.44
1Y
Price
Market Cap
$8.484b
Mid
Price/Earnings
-15.7x
-4.6x
3y Avg-4.6x
5y AvgDividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth
0.0%
-
3y CAGR-
5y CAGRPayout
0.0%
-
Payout 3y-
Payout 5yYield
BenchmarkDividends
No items found.
Financials Overview
Limited financial historyPremium
-8096.8%
EBITDA Margin-3388.2%
Net Profit Margin-
Free Cash Flow MarginRevenue
$221.902m
+2255.4%
1y CAGR+726.3%
3y CAGR+731.0%
5y CAGREarnings
-$535.762m
+29.4%
1y CAGR+7.3%
3y CAGR-2.5%
5y CAGREPS
-$2.85
+33.4%
1y CAGR+13.3%
3y CAGR+8.0%
5y CAGRBook Value
-$1.468b
$919.338m
Assets$2.377b
Liabilities$1.731b
DebtDebt to Assets
188.2%
-4x
Debt to EBITDAFree Cash Flow
-$529.634m
+7.0%
1y CAGR+1.6%
3y CAGR-7.3%
5y CAGRFinancial Reports
Limited financial historyPremium
No items found.
Press Releases
Statements and updates from the company